South Korea · Delayed Price · Currency is KRW LG Chem Earnings Call Transcripts
Fiscal Year 2025
-
Q4 2025 saw a return to net loss, driven by asset impairments and weak petrochemical and battery materials markets. The company is focusing on high-value-added products, portfolio restructuring, and prudent CAPEX, with 2026 revenue (ex-Energy Solution) targeted at KRW 23 trillion.
-
Q3 2025 marked a return to profitability with improved margins, driven by cost reductions and a one-time payment in Life Sciences. The outlook remains cautious amid weak demand and policy uncertainties, but growth is expected in high-value products and advanced materials.
-
Q2 profitability improved, led by Energy Solution and Life Sciences, despite ongoing tariff and demand headwinds. Advanced Materials and Petrochemicals face near-term challenges, but strategic portfolio shifts, local supply initiatives, and asset sales aim to drive future growth.
-
Q1 2025 saw improved profitability despite a challenging environment, with cost-cutting and high-value product sales offsetting slight sales declines. Ongoing tariff and policy volatility impact outlook, while strategic restructuring and investment in growth areas continue.
Fiscal Year 2024
-
2024 saw significant challenges from global oversupply and weak EV demand, resulting in lower sales and profitability. The company is focusing on restructuring, cost control, and selective investment, with 2025 CapEx plans reduced and a continued emphasis on positive cash flow.
-
Q3 saw improved sales and profitability, driven by Energy Solution and stable advanced materials, despite losses in petrochemicals and life sciences. CapEx was cut amid market uncertainty, with cautious outlooks for Q4 and 2025 as metal prices and inventory adjustments weigh on margins.
-
Q2 2024 saw improved results with KRW 12.3T sales and KRW 406B operating profit, but guidance for battery materials and cathode capacity was revised down due to weak EV demand and market volatility. CapEx plans were reduced, and profitability in life sciences was temporarily boosted by a licensing deal.